TABLE 2.
Recipient Characteristics at Time of LT
| Recipient Characteristic | Resident (n = 43,026) | Presumed Unauthorized Immigrants (n = 166) | P |
|---|---|---|---|
| Age (years) | 58 (51–63) | 49 (39–58) | <0.001 |
| Male | 28,336 (66) | 100 (60) | 0.13 |
| Medicaid as Payer of LT | 6,035 (14) | 85 (51) | <0.001 |
| Private Insurance as Payer of LT | 22,543 (52) | 53 (32) | <0.001 |
| Race/Ethnicity | |||
| Caucasian | 30,678 (71) | 29 (18) | <0.001 |
| Black | 3,889 (9) | 10 (6) | |
| Hispanic | 6,026 (14) | 98 (59) | |
| Asian | 1,789 (4) | 26 (16) | |
| Other | 644 (2) | 3 (2) | |
| Highest Education Level | |||
| High School or Below | 19,694 (46) | 102 (61) | <0.001 |
| College or Above | 21,576 (50) | 54 (32) | |
| Unknown | 1,756 (4) | 10 (6) | |
| Body Mass Index | 28.5 (25.0–32.7) | 26.7 (23.7–30.2) | 0.001 |
| Diabetes* | 12,138 (28) | 33 (20) | 0.05 |
| Renal Replacement Therapy | 6,621 (15) | 51 (31) | <0.001 |
| Portal Vein Thrombosis at LT† | 5,798 (14) | 22 (13) | 0.93 |
| MELD Score at LT | 21 (14–31) | 29 (20–37) | <0.001 |
| Simultaneous Liver Kidney Recipient | 3,710 (9) | 22 (13) | 0.03 |
| Living Donor | 1,723 (4) | 5 (3) | 0.51 |
| Days on Waitlist | 108 (20–307) | 56 (7–270) | <0.001 |
| indication‡ for LT | Resident (n = 43,026) | Presumed Unauthorized immigrants (n = 166) | P |
| Alcohol | 10,568 (25) | 38 (23) | 0.62 |
| Hepatitis C | 9,764 (23) | 22 (13) | 0.004 |
| Hepatitis B | 977 (2.3) | 16 (10) | <0.001 |
| Nonalcoholic Fatty Liver Disease or Cryptogenic | 8,083 (19) | 26 (16) | 0.30 |
| Autoimmune§ | 4,167 (9.7) | 18 (11) | 0.61 |
| Other | 3,103 (7.2) | 20 (12) | 0.02 |
| Hepatocellular Carcinoma | 14,703 (34) | 42 (25) | 0.2 |
Note: Data are presented as n (%) or median (IQR).
For diabetes status, 75 (0.2%) missing values among residents, 0 (0%) missing values among presumed unauthorized immigrants.
For portal vein thrombosis at LT, 237 (0.6%) missing values among residents, 0 (0%) missing values among presumed unauthorized immigrants.
The indication for transplant was categorized as hepatitis C, hepatitis B, alcohol-associated liver disease, nonalcoholic fatty liver disease, cryptogenic, autoimmune (includes autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis), and other (e.g., acute liver failure, drug-induced liver injury, Wilson’s, amyloidosis, glycogen storage diseases) based on primary listing diagnosis. The diagnosis of HCC was based on any primary or secondary diagnosis of HCC at listing or LT.
Includes autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cholangitis.